Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AVMXY OTCMKTS:OSIR NYSE:PLX NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APLXProtalix BioTherapeutics$1.91+5.5%$1.55$0.99▼$3.10$152.29M-0.23830,137 shs1.35 million shsPRMEPrime Medicine$4.01-1.5%$3.88$1.11▼$5.17$539.64M2.382.55 million shs2.36 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics0.00%+17.53%+22.30%+26.57%+72.38%PRMEPrime Medicine0.00%+9.41%+14.01%+171.33%-0.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APLXProtalix BioTherapeutics$1.91+5.5%$1.55$0.99▼$3.10$152.29M-0.23830,137 shs1.35 million shsPRMEPrime Medicine$4.01-1.5%$3.88$1.11▼$5.17$539.64M2.382.55 million shs2.36 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics0.00%+17.53%+22.30%+26.57%+72.38%PRMEPrime Medicine0.00%+9.41%+14.01%+171.33%-0.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVMXYAVITA MED LTD/S 0.00N/AN/AN/AOSIROsiris Therapeutics 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00685.34% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92122.36% UpsideCurrent Analyst Ratings BreakdownLatest AVMXY, OSIR, PRME, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVMXYAVITA MED LTD/S$5.51M118.31N/AN/A$0.26 per share30.35OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics$61.95M2.46$0.11 per share17.80$0.47 per share4.06PRMEPrime Medicine$4.96M108.78N/AN/A$1.37 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVMXYAVITA MED LTD/S-$24.75M-$0.39N/A∞N/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.07N/A6.16N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4536.06%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVMXYAVITA MED LTD/SN/A5.505.33OSIROsiris TherapeuticsN/AN/AN/APLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVMXYAVITA MED LTD/S0.01%OSIROsiris Therapeutics0.28%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipAVMXYAVITA MED LTD/SN/AOSIROsiris Therapeutics43.40%PLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVMXYAVITA MED LTD/S5582.62 millionN/ANot OptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableAVMXY, OSIR, PRME, and PLX HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Moderate Buy" by AnalystsSeptember 14 at 2:13 AM | marketbeat.comCathie Wood’s ARK ETF adjusts stock positions, buys PRME and TWSTSeptember 9, 2025 | investing.comPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comPrime Medicine Unveils New Prime Editing AdvancementsSeptember 8, 2025 | msn.comPrime Drink Group Terminates Rights Offering and Announces Private PlacementSeptember 4, 2025 | globenewswire.comPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comPrime Medicine, Inc. (PRME) Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 2, 2025 | seekingalpha.comPrime Medicine (NYSE:PRME) Stock Price Up 4.9% - Here's What HappenedAugust 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Has $8.25 Million Stake in Prime Medicine, Inc. $PRMEAugust 27, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comPositive Signs As Multiple Insiders Buy Prime Medicine StockAugust 20, 2025 | uk.finance.yahoo.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comAnalysts Set Expectations for Prime Medicine FY2025 EarningsAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Prime Medicine Cut by HC WainwrightAugust 16, 2025 | marketbeat.comPrime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial PositionAugust 8, 2025 | tipranks.comPRME Revenue Misses by 73%August 8, 2025 | aol.comAPrime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue EstimatesAugust 7, 2025 | zacks.comPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPrime Medicine Holds Special Stockholder MeetingAugust 5, 2025 | tipranks.comFriday’s Insider Trades: Key Buys and Sells in US Stocks RevealedAugust 4, 2025 | investing.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 SharesAugust 2, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVMXY, OSIR, PRME, and PLX Company DescriptionsAVITA MED LTD/S OTCMKTS:AVMXYAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Protalix BioTherapeutics NYSE:PLX$1.91 +0.10 (+5.52%) Closing price 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.31%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$4.01 -0.06 (-1.47%) Closing price 04:00 PM EasternExtended Trading$4.00 0.00 (-0.12%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
